These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23645886)

  • 1. Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes.
    Henry RR; Rosenstock J; Logan DK; Alessi TR; Luskey K; Baron MA
    Diabetes Care; 2013 Sep; 36(9):2559-65. PubMed ID: 23645886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment satisfaction with ITCA 650, a novel drug-device delivering continuous exenatide, versus twice-daily injections of exenatide in type 2 diabetics using metformin.
    Henry R; Rosenstock J; McCarthy JF; Carls G; Alessi T; Yee J; Baron M
    Diabetes Obes Metab; 2018 Mar; 20(3):638-645. PubMed ID: 29053202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes.
    Henry RR; Rosenstock J; Logan D; Alessi T; Luskey K; Baron MA
    J Diabetes Complications; 2014; 28(3):393-8. PubMed ID: 24631129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes.
    Henry RR; Logan D; Alessi T; Baron MA
    Clin Ther; 2013 May; 35(5):634-645.e1. PubMed ID: 23578605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA
    Henry RR; Rosenstock J; Denham DS; Prabhakar P; Kjems L; Baron MA
    Diabetes Care; 2018 Mar; 41(3):613-619. PubMed ID: 29301824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
    Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
    Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial.
    Rosenstock J; Buse JB; Azeem R; Prabhakar P; Kjems L; Huang H; Baron MA
    Diabetes Care; 2018 Feb; 41(2):333-340. PubMed ID: 29242349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).
    Rosenstock J; Raccah D; Korányi L; Maffei L; Boka G; Miossec P; Gerich JE
    Diabetes Care; 2013 Oct; 36(10):2945-51. PubMed ID: 23698396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.
    Iványi T; Fövényi J; Faludi P; Han J; Macconell L; Wille S; Kiljanski J
    Clin Ther; 2012 Jun; 34(6):1301-13. PubMed ID: 22608106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia.
    Gallwitz B; Böhmer M; Segiet T; Mölle A; Milek K; Becker B; Helsberg K; Petto H; Peters N; Bachmann O
    Diabetes Care; 2011 Mar; 34(3):604-6. PubMed ID: 21285388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of exenatide in Korean patients with type 2 diabetes inadequately controlled with oral hypoglycemic agents: an observational study in a real clinical practice.
    Hwang YC; Kim A; Jo E; Yang Y; Cho JH; Lee BW
    BMC Endocr Disord; 2017 Oct; 17(1):68. PubMed ID: 29065865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
    Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
    Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
    Klonoff DC; Buse JB; Nielsen LL; Guan X; Bowlus CL; Holcombe JH; Wintle ME; Maggs DG
    Curr Med Res Opin; 2008 Jan; 24(1):275-86. PubMed ID: 18053320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus.
    Wang Y; Xu B; Zhu L; Lou K; Chen Y; Zhao X; Wang Q; Xu L; Guo X; Ji L; Cui Y; Fang Y
    Clin Drug Investig; 2017 Dec; 37(12):1107-1115. PubMed ID: 28932995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of exenatide twice daily and exenatide once weekly in Asian versus White patients with type 2 diabetes mellitus: A pooled analysis.
    Sheu WH; Brunell SC; Blase E
    Diabetes Res Clin Pract; 2016 Apr; 114():160-72. PubMed ID: 26827116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus.
    Ratner RE; Maggs D; Nielsen LL; Stonehouse AH; Poon T; Zhang B; Bicsak TA; Brodows RG; Kim DD
    Diabetes Obes Metab; 2006 Jul; 8(4):419-28. PubMed ID: 16776749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of exenatide with biphasic insulin aspart 30 on glucose variability in type 2 diabetes: study protocol for a randomized controlled trial.
    Xu S; Liu X; Ming J; Ji Q
    Trials; 2016 Mar; 17():160. PubMed ID: 27009108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
    Kim D; MacConell L; Zhuang D; Kothare PA; Trautmann M; Fineman M; Taylor K
    Diabetes Care; 2007 Jun; 30(6):1487-93. PubMed ID: 17353504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of exenatide and acarbose on intra-abdominal fat content in patients with obesity and type-2 diabetes: A randomized controlled trial.
    Shi L; Zhu J; Yang P; Tang X; Yu W; Pan C; Shen M; Zhu D; Cheng J; Ye X
    Obes Res Clin Pract; 2017; 11(5):607-615. PubMed ID: 28161303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.